Clinical Research Directory
Browse clinical research sites, groups, and studies.
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Sponsor: Reunion Neuroscience Inc
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Official title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2026-04
Completion Date
2027-04
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
Placebo
Single, subcutaneous dose of 0.9% sodium chloride for injection